Project Grant HT94252510315
Award Date
5/1/25
Completion Date
4/30/27
Dollars Obligated
$829K
Federal Agency
Defense Health Agency
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
The federal Project Grant award of $481,158.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) enables Duke University to conduct research aimed at "Blocking Glutamine Utilization in Advanced and Therapy-Resistant Prostate Cancer." The award supports a two-year project from June 1, 2024 to May 31, 2026 to expand the frontiers of scientific knowledge and apply it to address a critical medical challenge facing military service...
The Defense Health Agency awarded Duke University a $1,167,250 Project Grant (CFDA 12.420 - Military Medical Research and Development) with a performance period from June 1, 2024 to May 31, 2027. The grant funding supports Duke's research on the role of the NLRP3-NLRC5 signaling pathway in melanoma immune evasion and dormancy. The research aims to advance the understanding of mechanisms underlying melanoma progression, with the potential to inform new therapeutic approaches. As a prominent...
The Defense Health Agency awarded Duke University a $3,811,150.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a research project titled "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant period runs from April 1, 2024 to March 31, 2028. The key products and services to be delivered under this award include comprehensive single-cell and spatial analysis of breast cancer samples to characterize tumor heterogeneity...
The Department of the Army Medical Command awarded Duke University a $547,664 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 2021 to May 2023 to exploit targeted therapy-induced ATM dependence in residual lung tumors. Through this award, Duke University researchers will investigate medical solutions for the battlefield by transforming health care for Service Members and the American public through innovative and...
This $819,841 federal Project Grant awarded by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), supports Duke University's research to pharmacologically activate a newly discovered KEAP1-ATF4-CHOP axis in order to select against targeted therapy resistance in non-small cell lung cancer (NSCLC). The research project aims to develop new treatments that can overcome resistance to existing targeted therapies for NSCLC. Duke University, through its...
This $241,500.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program will support research at Duke University to investigate the "UNDERSTANDING THE MOLECULAR COMMUNICATION BETWEEN PROSTATE CANCER CELL TYPES." The award period runs from September 1, 2025 to August 31, 2027. As a leading private research university, Duke University has a robust track record of securing federal grants and contracts...
The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
The Department of the Army Medical Command awarded Duke University a $784,385 Project Grant on September 30, 2022 to complete work by September 29, 2025. The grant supports the "Modulation of Tumor Microenvironment to Hinder Cancer Progression and Therapeutic Resistance" project under the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and public health through innovative biomedical research solutions. Duke University will...
The federal Project Grant award of $724,500.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Duke University to investigate "Targeting Dormancy-Associated Immune Tolerance to Eliminate Residual Breast Cancer." This award, with a performance period from March 1, 2025 to February 29, 2028, will fund advanced medical research to explore innovative approaches for treating breast cancer, with a focus on...
The Defense Health Agency awarded Duke University a $483,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of March 1, 2021 through February 28, 2024. The grant funding will support Duke University's research project "Targeting Glutamine Utilization in Therapy-Resistant Prostate Cancer." The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research...